Skip Navigation


Annals of Oncology Advance Access originally published online on April 13, 2007
Annals of Oncology 2007 18(7):1243-1245; doi:10.1093/annonc/mdm107
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/7/1243    most recent
mdm107v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nair, R
Right arrow Articles by Parikh, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nair, R
Right arrow Articles by Parikh, P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

supportive care

The effect of short-term intensive chemotherapy on reactivation of tuberculosis

R Nair1, K Prabhash1, M Sengar1, A Bakshi1, S Gujral2, S Gupta1 and P Parikh1,*

1 Department of Medical Oncology
2 Department of Pathology, Tata Memorial Hospital, Mumbai, Parel, Mumbai-400012, India

* Correspondence to: Dr P. Parikh, Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai-400012, India. Tel: 22-24177213; Fax: 22-24161574; E-mail: medicaloncology{at}tatahospital.org

Background: Various malignancies and cytotoxic chemotherapy have been proposed to increase the risk of reactivation of tuberculosis. Available literature to support this observation is still conflicting. There is scarcity of data from countries with rampant tubercular infection, such as India, in this regard.

Design and methods: In the present retrospective analysis, patients with high-grade non-Hodgkin's lymphoma with past history of tuberculosis and have had adequate antitubercular therapy were identified from a Lymphoma Group study. These patients were followed up during cytotoxic chemotherapy and later to assess the risk of reactivation.

Results: A cohort of eight patients with past history of tuberculosis was selected from 141 patients of high-grade non-Hodgkin's lymphoma. The median age was 33.5 years (range, 24–53 years). Median duration between completion of antitubercular treatment and diagnosis of lymphoma was 5 years (range, 1.5–10 years). All patients received cyclical cytotoxic chemotherapy. The median duration of follow up after completion of chemotherapy was 5 years (range, 10 months to 5 years). None of these patients developed reactivation of tuberculosis.

Conclusion: Cyclical chemotherapy for non-Hodgkin's lymphoma does not lead to reactivation of tuberculosis.

Key words: cyclical chemotherapy, cytotoxic chemotherapy, lymphoma treatment, non-Hodgkin's lymphoma, reactivation, tuberculosis

Received for publication December 30, 2006. Accepted for publication February 19, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2007 18: 1127. [Extract] [FREE Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.